“The biggest finding is that we are seeing a steady increase in women representation in the field of urology,” says Teresa L. Danforth, MD.
In this video, Teresa L. Danforth, MD, discusses the background and notable findings from the study, “Closing the Gender Gap in the Urology Residency Match,” which was presented at the Northeastern Section of the American Urological Association Annual Meeting in Charlotte, North Carolina.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.